Episodes (Page 4)
✨
Building trust with patients of diverse skin tones is crucial.
Jennifer Soung, MD
Mona Shahriari, MD
✨
AI is rapidly evolving and impacting medicine, especially cardiology.
Manish Wadhwa, MD
✨
Corticosteroid stewardship means intentional, not avoided, use.
✨
Finerenone is the first new therapy for CKD in type 1 diabetes in 30 years.
Diana Isaacs
Natalie Bellini
✨
Psoriasis presentation differs significantly across diverse skin tones.
Diverse Skin Types
✨
Dapagliflozin reduces cardiovascular death or HF worsening regardless of setting.
✨
Antihypertensive medications consistently reduce cardiovascular disease risk.
✨
ENCORE trial shifted focus to patient-reported symptoms as primary endpoint.
✨
Finding effective comparators for psilocybin trials is challenging.
✨
Early amikacin liposome inhalation (ALIS) cuts MACLD recurrence.
✨
Fluconazole linked to improved disease activity in IBD patients.
✨
Dr. Woolley defends UMBRAA, a blinding framework for psilocybin trials.
✨
CMR GUIDE trial missed primary endpoint but showed potential ICD benefit.
✨
Fluconazole linked to improved IBD activity scores.
✨
Finerenone approved for CKD in type 1 diabetes.
✨
FDA accepted NDA for zasocitinib for plaque psoriasis.
✨
Zasocitinib showed high skin clearance in phase 3 trials.
✨
CMR GUIDE trial did not reduce sudden cardiovascular death.
✨
Candida migration from mouth to gut in IBD discussed.
✨
UMBRAA framework proposed to fix psilocybin trial blinding.